WallStreetZenWallStreetZen

NASDAQ: SAGE
Sage Therapeutics Inc Earnings & Revenue

SAGE past revenue growth

How has SAGE's revenue growth performed historically?
Company
1,024.84%
Industry
188.87%
Market
18.51%
SAGE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SAGE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SAGE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SAGE earnings and revenue history

Current Revenue
$86.5M
Current Earnings
-$541.5M
Current Profit Margin
-626.3%

SAGE Return on Equity

Current Company
-58%
Current Industry
-64.7%
Current Market
188%
SAGE's Return on Equity (-58%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SAGE announces earnings.

SAGE Return on Assets

Current Company
-52.4%
Current Industry
6.6%
SAGE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SAGE Return on Capital Employed

Current Company
-67.73%
Current Industry
23.6%
SAGE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SAGE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SAGE$86.46M-$540.10M-$541.49M-0.86%N/A
ADMA$258.22M$5.12M-$28.24M+72.34%N/A
AMLX$380.79M$55.39M$49.27M+304.24%N/A
VERV$11.76M-$187.55M-$200.07M+505.77%N/A
ETNB$0.00-$133.26M-$142.19MN/AN/A

SAGE earnings dates

Next earnings date
Apr 30, 2024

Sage Therapeutics Earnings & Revenue FAQ

What were SAGE's earnings last quarter?

On Invalid Date, Sage Therapeutics (NASDAQ: SAGE) reported Q4 2023 earnings per share (EPS) of -$0.54, up 78.14% year over year. Total Sage Therapeutics earnings for the quarter were -$32.71 million. In the same quarter last year, Sage Therapeutics's earnings per share (EPS) was -$2.47.

If you're new to stock investing, here's how to buy Sage Therapeutics stock.

What was SAGE's earnings growth in the past year?

As of Q1 2024, Sage Therapeutics's earnings has grown year over year. Sage Therapeutics's earnings in the past year totalled -$541.49 million.

What is SAGE's earnings date?

Sage Therapeutics's earnings date is Invalid Date. Add SAGE to your watchlist to be reminded of SAGE's next earnings announcement.

What was SAGE's revenue last quarter?

On Invalid Date, Sage Therapeutics (NASDAQ: SAGE) reported Q4 2023 revenue of $77.97 million up 2,621.54% year over year. In the same quarter last year, Sage Therapeutics's revenue was $2.87 million.

What was SAGE's revenue growth in the past year?

As of Q1 2024, Sage Therapeutics's revenue has grown 1,024.84% year over year. This is 835.96 percentage points higher than the US Biotechnology industry revenue growth rate of 188.87%. Sage Therapeutics's revenue in the past year totalled $86.46 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.